PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1954584
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1954584
The global transrectal ultrasound market size was valued at USD 271.11 million in 2025 and is projected to grow from USD 287.97 million in 2026 to USD 489.64 million by 2034, registering a CAGR of 6.90% during the forecast period (2026-2034). North America dominated the market with a 29.10% share in 2025, driven by a high prevalence of prostate cancer, advanced healthcare infrastructure, and favorable reimbursement policies.
Transrectal ultrasound (TRUS), also known as endorectal ultrasound or prostate sonogram, is a minimally invasive imaging technique used primarily for diagnosing prostate-related conditions such as prostate cancer, benign prostatic hyperplasia (BPH), and prostatitis. The procedure involves inserting a probe into the rectum to produce detailed images of the prostate using sound waves. TRUS plays a crucial role in prostate cancer screening, biopsy guidance, and image-guided therapies.
COVID-19 IMPACT
The COVID-19 pandemic significantly affected the market in 2020 due to a decline in urological procedures and postponement of elective surgeries. Several healthcare systems prioritized COVID-19 patients, leading to delays in prostate cancer screenings and diagnostic imaging. However, between Q4 2020 and Q1 2021, elective procedures gradually resumed, stabilizing market demand. From 2022 onwards, the market witnessed steady recovery, and growth is expected to continue through 2034.
MARKET OVERVIEW & KEY METRICS
MARKET TRENDS
Launch of Advanced Imaging and AI-Integrated Systems
Leading companies are increasingly launching innovative ultrasound platforms with enhanced imaging capabilities. Technologies such as MRI-US fusion biopsy, high-resolution micro-ultrasound, and real-time elastography are transforming prostate cancer diagnostics.
For example, the ExactVu micro-ultrasound platform uses a 29 MHz frequency to provide detailed visualization of prostate tissues. In April 2023, EDAP TMS received regulatory approval in Japan to commercialize its ExactVu micro-ultrasound biopsy system. Additionally, AI-based imaging tools are being developed to improve diagnostic precision. Studies published in 2023 highlight the growing role of artificial intelligence in differentiating prostate cancer using TRUS images, improving biopsy guidance and diagnostic outcomes.
MARKET GROWTH FACTORS
Increasing Prevalence of Prostate Cancer
Prostate cancer is one of the most common cancers among men globally. According to the World Cancer Research Fund International, prostate cancer is the second most frequently occurring cancer in men, with over 1.4 million new cases reported worldwide in 2020. Rising incidence rates over the past two decades have significantly increased the demand for early detection and diagnostic imaging technologies such as TRUS.
Strong Reimbursement Policies and Government Initiatives
Supportive reimbursement frameworks and awareness programs are encouraging early diagnosis. Initiatives such as funding programs for prostate cancer research and screening awareness campaigns are promoting the adoption of advanced diagnostic technologies. Conferences and policy initiatives focusing on ultrasound reimbursement strategies have further strengthened the market landscape.
RESTRAINING FACTORS
Despite technological advancements, the market faces challenges including product recalls and regulatory scrutiny. For instance, recalls of certain ultrasound systems in previous years have affected adoption rates. Additionally, a shortage of trained technicians and urologists, particularly in developed countries, may limit procedural capacity. Stringent regulatory requirements also increase compliance costs for manufacturers.
MARKET SEGMENTATION ANALYSIS
By Product
The market is segmented into systems and transducers.
By Type
The market is divided into cart/trolley-based and portable systems.
By Application
The market is segmented into diagnostic and image-guided treatment.
By End-User
The market is categorized into hospitals & ASCs, diagnostic laboratories, and others.
REGIONAL INSIGHTS
North America
North America generated USD 78.89 million in 2025 and remained the leading region due to high prostate cancer prevalence and strong healthcare infrastructure. Increased awareness and screening initiatives are further driving growth.
Europe
Europe is projected to record a significant CAGR, supported by government initiatives promoting early prostate cancer detection and regulatory approvals for advanced biopsy solutions.
Asia Pacific
Asia Pacific is expected to witness strong growth due to expanding healthcare infrastructure, replacement of outdated ultrasound systems, and increasing healthcare expenditure in countries such as China, India, and Japan.
Latin America & Middle East & Africa
These regions are anticipated to grow at a comparatively lower CAGR due to limited awareness and lower healthcare spending, though gradual improvements in diagnostic access are expected.
KEY INDUSTRY PLAYERS
Major companies operating in the market include:
These players focus on acquisitions, product innovation, and regulatory approvals to strengthen their competitive position.
KEY INDUSTRY DEVELOPMENTS
CONCLUSION
The global transrectal ultrasound market is projected to grow from USD 271.11 million in 2025 to USD 489.64 million by 2034, expanding at a CAGR of 6.90%. The market is expected to reach USD 287.97 million in 2026, supported by increasing prostate cancer prevalence, advancements in AI-integrated imaging systems, and favorable reimbursement policies. Although challenges such as regulatory scrutiny and technician shortages persist, continuous technological innovation and growing awareness of early cancer detection are expected to sustain long-term market growth through 2034.
Segmentation By Product
By Type
By Application
By End-user
By Region